An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Izutsu, Koji; Makita, Shinichi; Nosaka, Kisato; Yoshimitsu, Makoto; Utsunomiya, Atae; Kusumoto, Shigeru; Morishima, Satoko; Tsukasaki, Kunihiro; Kawamata, Toyotaka; Ono, Takaaki; Rai, Shinya; Katsuya, Hiroo; Ishikawa, Jun; Yamada, Hironori; Kato, Kazunobu; Tachibana, Masaya; Kakurai, Yasuyuki; Adachi, Nobuaki; Tobinai, Kensei; Yonekura, Kentaro; Ishitsuka, Kenji

doi:10.1182/blood.2022016862

Public

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Shared by NobleBlocks on Sep 23, 2022 • 12:00 AM UTC

Authors:

Koji Izutsu

Shinichi Makita

Kisato Nosaka

Abstract

Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. We evaluated the efficacy and safety of valemetostat, a potent enhancer of zeste homolog 2 (EZH2) and EZH1 inhibitor,...

Subject

Medicine

Neutropenia

Leukopenia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!